|CHDD||Home | Site Map | Search | Directory | Admin Services||
||Center on Human Development and Disability|
|About CHDD | IDDRC | UCEDD|
Dr. Isoherranen’s research focuses on changes in drug metabolism during pregnancy and mechanisms by which drug disposition changes during pregnancy. Her laboratory has developed special expertise in modeling and simulation of maternal-fetal disposition of xenobiotics across the gestational timeline and in evaluating the magnitude of changes in drug disposition during pregnancy. There is now considerable evidence that the expression and activity of various metabolic enzymes and transporters are significantly altered during pregnancy. This may lead to decreased exposures to therapeutic compounds during pregnancy leading to therapeutic failure of treatments such as anti-infectives, antiepileptics, and drugs used to treat gestational hypertension, diabetes, depression, and addiction. Such therapeutic failures put the developing baby at risk for developmental disabilities and other adverse effects. In addition, altered metabolism during pregnancy may increase the maternal and fetal exposure to harmful metabolites that have direct toxic effects to the fetus.
For more information on her research activities please see Nina Isoherranen's page on the Isoherranen Lab website
University of Washington • Center on Human Development and Disability • Box 357920 • Seattle WA 98195-7920 USA • 206-543-7701 • firstname.lastname@example.org
Copyright © 1996—2017 Center on Human Development and Disability. Updated: September 16, 2021